Liraglutide

Description

Product name: Liraglutide

Catalog#: 1208004-2

Synonyms: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37],

CAS NO.: 204656-20-2

Sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(γ-Glu-palmitoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

M.W: 3751.26

M.F.: C172H265N43O51

Purity: 95%

Counter ion: Trifluoacetate

Format: Lyophilized powder

Description: Liraglutide is a GLP-1 analogue that has 97% structural homology to native GLP-1 and is used in the treatment of type2 diabetes as it has proved effectiveness in all LEAD trials (monotherapy or combination therapy) in reducing HbA1c and weight in all patients regardless of their ethnicity, weight and sex. Liraglutide is a GLP-1 analog with pharmacokinetic properties suitable for once-daily administration that controls appetite, decreases body weight and improves glycemic control. Liraglutide 3.0 mg daily dose is marketed under the brand name Saxenda and was recently approved by both the Food and Drug Administration (FDA) and the European Medicine Agency (EMA) as adjunct to a comprehensive lifestyle intervention to achieve weight loss.

Drug Bank ID: http://www.drugbank.ca/drugs/DB06655

 

Usage: For Scientific Research Use Only, Not for Human Use.